Abstract. The aim of the present study was to investigate whether endometriosis and cancer share common molecular characteristics. Tissue samples were collected prospectively during diagnostic laparoscopy of patients with primary infertility. Using high-density oligonucleotide microarrays, (Affymetrix Gene Chip HG-U133 Set) the genome-wide gene expression profile of advanced ovarian endometriosis was analyzed compared with matched normal endometrium. Expression of TERT, the gene encoding the telomerase reverse transcriptase subunit, and telomerase activity were analyzed in eutopic and ectopic endometrium. Genome-wide, highresolution array-CGH was used to screen for genomic aberrations in endometriosis. Expression microarray data were validated quantitatively with RT-PCR. The genes RARRES1 and RARRES2 (retinoic acid receptor responder 1 and 2) were found to be up-regulated in endometriosis, suggesting a high degree of differentiation. Consistently, down-regulated genes included those involved in the cell cycle, cell metabolism and homeostasis. Expression of TERT and telomerase activity were present in eutopic but absent in ectopic endometrium. Array-CGH revealed a normal genomic pattern without gross amplifications and deletions. In conclusion, these data suggest that advanced ovarian endometriosis represents a highly differentiated tissue with minimal or no malignant potential.
Introduction
Endometriosis is the presence of endometrial tissue, including endometrial glandular and stromal cells, outside the uterine cavity. It is usually confined to the pelvis, where it may be associated with pelvic pain and infertility, and in rare cases it can be found in distant sites, such as the thorax and skin (1, 2) . It is estimated that endometriosis affects 5-15% of 'normal' and up to 60-80% of women with pelvic pain and/or infertility (3) .
The most widely accepted theory on the etiopathogenesis of endometriosis is the theory of ectopic transplantation of endometrium, mainly through reflux menstruation (4) . Similarly, endometriosis in distant sites can be explained by migration of endometrial cells through lymphatic and blood vessels (5) . In this way, endometriosis represents a paradigm of benign dissemination and metastasis. At the cellular level it is characterized by monoclonal growth and can reveal features of malignant behaviour including local invasion and metastasis (6) . Therefore, endometriosis might serve as a model to study the molecular and genomic requirements needed for dissemination of non-malignant cells.
The association of endometriosis with cancer is unclear. Although it is not neoplastic and does not create a cachectic or catabolic state, certain processes characterizing metastasis and carcinogenesis are also seen in endometriosis. These include cell motility, adhesion, homing and invasion, immunologic factors, maintenance of the original structure and tissue architecture at the ectopic site, angiogenesis and metaplasia (6) . Moreover, evidence exists that endometriotic lesions present genetic changes similar to certain malignancies (7, 8) . Furthermore, a direct association of ovarian cancer and endometriosis has been previously described in numerous case reports and case series (9) (10) (11) (12) . Like any other tissue, endometriotic lesions may well undergo malignant transformation. On the other hand, large retrospective, epidemiologic studies show that women with endometriosis have an increased risk of ovarian and other types of cancer compared with the normal population (13, 14) .
Given the multitude of cellular and molecular mechanisms involved in endometriosis formation and maintenance and the gap of knowledge concerning the association of endometriosis with tumorigenesis and metastasis, we conducted a large-scale gene expression analysis of ovarian endometriotic lesions and corresponding eutopic endometrium. To examine for genomic variations which might influence the gene expression profile, we performed an array-CGH analysis on selected endometriotic tissue samples, including samples analyzed with gene expression microarrays.
Materials and methods
Tissue samples. Tissue samples were collected prospectively from patients with primary infertility, who underwent laparoscopy during the proliferative phase of the menstrual cycle, between day 4 and 10 after the last menstrual period. All patients tested negative on a urine pregnancy test, had an otherwise healthy medical history, and were not under any hormone treatment. A total of 14 endometriotic ovarian cysts were excised, with operative time ranging between 30 and 45 min in all cases. All patients had moderate to severe endometriosis -stages III and IV according to the Revised American Fertility Society Classification for Endometriosis. Biopsies of normal endometrium were possible in four of these cases. Diagnosis was confirmed with histopathological examination in all cases. Biopsy material was stored in liquid nitrogen immediately after surgery (10-30 min after excision). An independent academic board approved the protocol prior to the study, and all specimens were obtained in accordance with the Declaration of Helsinki of 1975 on Human Experimentation. For microarray studies, only endometriotic lesions with matched eutopic endometrium available were used (i.e. four cases). For array-CGH analysis, 10 endometriosis samples were used including the 4 cases from the gene expression analysis.
RNA preparation. Tissue specimens were homogenized in liquid nitrogen using pestle and mortar. Total RNA was prepared by lysing specimens in Trizol reagent according to the manufacturer's instructions (Invitrogen GmbH, Karlsruhe, Germany). Total RNA was cleaned-up using RNeasy Mini Kit according to the manufacturer's instructions (Qiagen GmbH, Hilden, Germany).
DNA preparation. All cryopreserved tissue samples were homogenized, and genomic DNA was isolated using the Qia-DNA Isolation Kit (Qiagen GmbH) according to the manufacturer's instructions.
Gene expression profiling.
For all experiments, high-density oligonucleotide microarrays, screening for >40,000 human genes and expressed sequence tags ESTs (44,928 probe sets) were used (GeneChip HG-U133 Set; Affymetrix, Santa Clara, CA). The targets for DNA-microarray analysis were prepared as described by the manufacturer. In brief, after RNA extraction, reverse transcription, cDNA clean-up, in vitro transcription and cRNA-labelling with biotin and fragmentation, cRNA was hybridized on the microarrays. The amount of total RNA used for cDNA-synthesis was 10 μg for each reaction. GeneChip microarrays were hybridized with the targets for 16 h at 45˚C, and then washed and stained using the Affymetrix Fluidics Station according to the GeneChip Expression Analysis Technical Manual. Microarrays were scanned with a Hewlett-Packard-Agilent GeneChip scanner, and the signals were processed using the GeneChip expression analysis algorithm ver. 2 (Affymetrix). To compare samples and experiments, the trimmed mean signal of each array was scaled to a target intensity of 200 for A-Arrays and 80 for BArrays. Absolute and comparison analyses were performed with Affymetrix MAS 5.0 and DMT software using default parameters. In order to identify genes positively or negatively regulated, genes that were increased or decreased at least 2-fold compared to the baseline (eutopic endometrium) were selected (15) . Annotations were further analyzed with interactive query analysis at www.affymetrix.com. Pathways and other functional groupings of genes were evaluated for differential regulation using the visualization tool GenMAPP (UCSF) as described previously (16, 17) .
Radioactive RT-PCR. First-strand cDNA synthesis was performed using 1 μg total RNA with the ThermoScript Reverse Transcriptase Kit (Invitrogen, Carlsbad, CA, USA) in the presence of 100 ng oligo-dT 20 in a volume of 20 μl under the following conditions: 1 h at 50˚C followed by 15 min at 75˚C, followed by 20 min at 37˚C in the presence of 2 units of RNase H to digest the RNA. cDNA (2 μl) was used for the PCR analysis in a total volume of 50 μl containing 0.2 μM specific primers, 10% DMSO, 1.5 mM MgCl 2 , 0.2 mM dNTPs and 1 unit of Taq polymerase (Eppendorf, Hamburg, Germany). The sequences of primers used were: RARRES1, 5'-GAG CGC TAC AAC CCA GAG TC-3' (forward) and 5'-GAA AGC CAA ATC CCA GAT GA-3' (reverse); RARRES2, 5'-GAC TGG AAG AAA CCC GAG TG-3' (forward) and 5'-CTT GGA GAA GGC GAA CTG TC-3' (reverse); LTBP2, 5'-CTG AAT CCG CCC AGT GAT AG-3', (forward) and 5'-ACA TTG GAA ATC TGG CTG CT-3' (reverse); TYMS, 5'-TTC AGG ACA GGG AGT TGA CC-3' (forward) and 5'-CAT GTC TCC CGA TCT CTG GT-3' (reverse); HMGCR, 5'-TCT CCG CAG GCT ATT TGT TC-3' (forward) and 5'-TAA GGT CCC AGT CTT GCT TG-3' (reverse); hTERT, 5'-TCT GGA TTT GCA GGT GAA CAG CC-3' (forward) and 5'-GGG TGG CCA TCA GTC CAG GAT GG-3' (reverse); 36B4, 5'-GTG GGA GCA GAC AAT GTG GGC TCC-3' (forward) and 5'-ATG GAT CAG CCA AGA AGG CCT TGA C-3' (reverse); 18Sr RNA, 5'-GTT GCA AAG CTG AAA CTT AAA GG-3' (forward) and 5'-CCG ATC CGA GGG CCT CAC TAA ACC-3' (reverse). For radioactive PCR analysis, 2.5 μCi of [α-32 P] dCTP (3000 Ci/ mmol, Amersham Pharmacia Biotech, Freiburg, Germany) was added to the reaction. Amplification products were analyzed on 4% (36B4, 18Sr RNA and hTERT) or 6% (RARRES1, RARRES2, LTBP2, TYMS and HMGCR) nondenaturing polyacrylamide gels, respectively.
Array-CGH. Array-CGH was carried out as described previously (18) . In brief, endometriotic DNA and reference normal male DNA were labelled by random priming (BioPrime DNA labelling system, Invitrogen, Breda, The Netherlands) to incorporate Cy3-dCTP and Cy5-dCTP (Perkin-Elmer Life Sciences, Zaventem, Belgium), respectively. Non-incorporated nucleotides were removed using ProbeQuant G-50 Microcolumns (Amersham Biosciences, Roosendaal, The Netherlands). Hybridization was carried out with labelled DNA mixed with Cot-1 DNA (Invitrogen) for 2 days to the in-house-developed Bacterial Artificial Chromosome array containing 5,659 clones spotted in triplicate, which provides an ~1.0-Mb resolution across the human genome. Log2 ratios of Cy3 and Cy5 intensities for each spot were calculated. Data were processed as described (18) and plotted relative to the position of the clones. Table I . Up-regulated genes and ESTs in all 16 comparisons. Smoothing with data was performed using the aCGHsmooth program (http://www.few.vu.nl/~vumarray/) to detect genomic aberrations.
Determination of telomerase activity (TRAP assay).
In order to determine the enzymatic activity of telomerase in extracts from endometriotic and normal endometrium tissue samples, the Telomeric Repeat Amplification Protocol (TRAP) with the Trapeze Kit (Serologicals Corp., Norcross, GA, USA) was used, according to the manufacturer's instructions.
Results
Microarray data analysis. For data analysis, gene expression of the endometriotic lesion of each patient was compared to that of the eutopic endometrium of all 4 patients. In this way, the expression profiles of all 4 endometriotic lesions were compared to 4 different reference probes, leading to a total of 16 comparisons. Using this strategy, two groups of genes were identified. The first included 14 up-regulated (Table I) , and the second included 22 down-regulated genes and ESTs in all 16 comparisons (Table II) . Furthermore, 56 additional genes and ESTs were up-regulated in 15 out of 16 comparisons (Table III) , and an additional 75 genes and ESTs were down-regulated in 15 out of 16 comparisons (Table IV) .
Validation of microarray data. Expression of the following genes was used for initial in silico validation: MAGE-A1 and 2, MAGE-B1-4, MAGE-C1, BAGE and GAGE1-4 and 6-7. These genes are expressed only in malignancies but not in normal tissues, with some rare exceptions (e.g. normal testis and placenta) (19) . Consistent with their tumor-associated expression pattern, all of these genes exhibited an 'absent call' in all samples tested with high-density oligonucleotide microarrays.
Five genes were selected for microarray data validation with RT-PCR. Four of these genes, RARRES1, LTBP2, TYMS, and HMGCR, showed significant variation in all 16 comparisons. There were two probe sets corresponding to RARRES1. The first (Affymetrix 221872_at) showed a 7.24-fold-up, and the second (206392_s_at) a 5.66-fold-up variation. LTBP2 showed a 3.72-fold-up, TYMS a 5.14-fold-down, and HMGCR a 3.07-fold-down variation. The fifth gene, RARRES2, was up-regulated in 14 out of 16 comparisons (21-fold-up). RARRES1 and 2 were selected as members of the same gene family, while LTBP2, TYMS, and HMGCR were randomly selected among genes showing significant variation.
Radioactive RT-PCR was used to detect and quantify expression of these genes (Fig. 1) . For this purpose, total RNA was freshly isolated from the eutopic (normal) endometrium and corresponding ectopic tissue from 3 patients (no material was left for RNA isolation from patient 4 for these studies). The signals were quantified and normalized to the average signal values obtained from two different ubiquitously expressed genes, 36B4 and 18S rRNA, to minimize tissuespecific variation in the expression of the control genes (Fig. 1A) . We found up-regulation of RARRES-1 (in average 15-fold), RARRES-2 (in average 9-fold) and LTBP-2 (in average 7-fold) (Fig. 1) , and down-regulation of HMGCR (in average 3.5-fold) and TYMS (in average 3-fold). Thus, RT-PCR Table II . Down-regulated genes and ESTs in all 16 comparisons. 
results confirmed the microarray data. Differences in signal intensities between RT-PCR and microarray results were probably due to the different numbers of patients analyzed with the two methods, and inherent methodological differences. The expression of these genes was also analyzed by RT-PCR in endometriotic lesions from 10 additional patients, and the results were in line with those described above, with negligible variations between patients (data not shown).
Lack of telomerase activity and hTERT gene expression in ectopic endometrium. Telomerase activity is repressed in most human somatic tissues during differentiation processes, but it is strongly up-regulated in the vast majority of tumors. Telomerase activity has been previously detected in normal endometrium (20), but it has not been examined in endometriosis. Regulation of telomerase activity occurs primarily at the level of transcriptional initiation of the hTERT (human telomerase reverse transcriptase) gene (21, 22) . Thus, the presence or absence of TERT gene mRNA, and consequently telomerase activity, may be indicative of the proliferative capacity of a given cell, a prerequisite for malignancy. hTERT exhibited an 'absent call' on the microarray analysis in all 8
probes tested (4 ectopic and 4 eutopic endometrium probes). We reasoned that this might be due to very low levels of hTERT mRNA (23) . For this reason, a very sensitive method, radioactive RT-PCR, was used to detect low levels of mRNA. hTERT mRNA was detectable in all normal endometrium samples, but completely absent in endometriosis samples ( Fig. 2A) . Moreover, telomerase activity was detectable in samples from normal endometrium but absent in endometriosis samples (Fig. 2B) .
Array-CGH analysis of endometriotic lesions. Array-CGH was performed on selected endometriotic tissues (including the samples used in the gene expression analysis) in order to screen for genomic aberrations, which could possibly influence gene expression. Identification of such aberrations could also provide indications of the possible association between endometriosis and neoplastic disease, and endometriosis dissemination. Genomic information obtained with conventional CGH is limited to a resolution of ~10 Mb, since the target DNA is highly condensed and supercoiled within the chromosome. Thus, array-based CGH was used in order to achieve a resolution approaching 1 MB. For automated identification of breakpoints and smoothing of array-CGH data the aCGHsmooth program was used as described previously (24) . Reliability of array-CGH results was confirmed through hybridization of the female endometriotic DNA with male reference DNA. As expected, DNA gain was detected on chromosome X (numbered as chromosome 23), while DNA loss was detected on chromosome Y (chromosome 24). Representative examples are shown in Fig. 3A and B.
No genomic aberrations were detected in any of the analyzed endometriotic lesions (Fig. 3) .
Discussion
Large-scale gene expression analyses of endometriosis and normal endometrium have been previously reported (25) (26) (27) (28) , but only a subset of the human genome was analyzed in these studies with various methodological approaches. In the present study, gene expression profiles of advanced ovarian endometriotic lesions and corresponding normal endometrium were analyzed with high-density oligonucleotide microarrays, covering for the first time almost the entire human genome by screening for >40,000 human genes and ESTs. Notably, all biopsies in this study were taken in the proliferative phase, since gene expression profiles in the eutopic endometrium differ between the two phases of the menstrual cycle (29) . Furthermore, the microarray method used allowed robust data analysis, since signal intensities of each sample could be compared to those of any other sample generated under the same experimental conditions, and thus more than one normal endometrium sample could be used as reference. Moreover, normal and ectopic endometrium samples were taken from the same patients, allowing gene expression analysis with minimal genetic background heterogeneity. Genetic heterogeneity between individuals confounds the comparison of gene expression profiles between individual patients. CGH with parallel gene expression microarray analyses have shown that individual genetic alterations can directly lead to gene expression dysregulation (30) . These RT-PCR and TRAP assays were performed as described in Materials and methods. For radioactive PCR, the same cDNA was used as in Fig. 1 and amplification (94˚C, 30 sec; 55˚C, 30 sec; 72˚C, 1 min) was performed for 28 cycles for hTERT. The loading controls (18S rRNA and 36B4 mRNA levels) are shown in Fig. 1 . M, 100 base pair ladder. One microgram of the 100 base pair ladder was end-labelled according to standard procedures, and ~1000 cps was loaded per lane.
limitations can be eliminated only in rare cases in which the patient and the healthy control are genetically identical, as is the case with identical twins; this approach has been previously used in two microarray studies, involving identical twins discordant for type I diabetes (31) and multiple myeloma (32) . In the present study, microarray data were analyzed with a minimal genetic background approach, comparing in essence four sets of 'identical twin' probes, as previously described (31, 32) .
Though studies with conventional CGH with human metaphase chromosomes (33, 34) , allowing a resolution of 10 MB, and high-resolution CGH (35) have previously described certain aberrations in endometriotic epithelial cells, our analysis by array-CGH to a much higher resolution of 1.0 Mb did not show any specific genomic aberrations in endometriosis samples. This contradiction is probably due to different experimental settings, patient characteristics, and disease stages. Moreover, genome variations such as segmental --------------------------------------------------------------------------------------------------------- -Table IV . Down-regulated genes and ESTs in 15 out of 16 comparisons. (Tables II and IV) . These genes have not been identified by previous microarray analyses of endometriosis, apparently due to different methodological approaches, lower number of genes analyzed in previous studies, and different subsets of patients, as discussed above.
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Altogether, our results showing up-regulation of putative tumor-suppressor genes such as RARRES1 and RARRES2 and down-regulation of genes involved in the cell cycle suggest that advanced ovarian endometriosis is a highly differentiated tissue with minimal proliferative capacity. Moreover, these conclusions are further supported by the absence of both hTERT gene expression and telomerase activity with a distinct methodological approach. This state of high tissue differentiation does not allow definitive conclusions to be made with respect to the etiopathogenesis of endometriosis, but overall, these data suggest that advanced ovarian endometriosis is unlikely to be a precursor lesion of cancer. The lack of detectable genomic aberrations in endometriosis with highresolution array-CGH analysis is in line with these findings. Modulated genes identified in this setting should be further evaluated individually in order to define their role in endometriosis. 
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